A Patient Perspective on Gene Therapy for Neuromuscular Diseases: Justin Moy
March 26th 2024The second-year PhD student in bioinformatics at Boston University who lives with LAMA2 congenital muscular dystrophy talked about the potential impact and challenges of gene therapy in neuromuscular diseases. [WATCH TIME: 5 minutes]
Challenges in Transitioning Care for Duchenne Muscular Dystrophy: Diana Castro, MD
March 25th 2024The neuromuscular specialist at the Neurology & Neuromuscular Care Center discussed the pressing need to address the transition of care from pediatric to adult healthcare systems in Duchenne muscular dystrophy. [WATCH TIME: 6 minutes]
Enhancing Multidisciplinary Care for Neuromuscular Disorders: Amanda Peltier, MD
March 25th 2024The professor of neurology at Vanderbilt University Medical Center talked about the importance of multidisciplinary care centers to improve accessibility and quality of care for patients with neuromuscular disorders. [WATCH TIME: 5 minutes]
FDA Approves Alexion's Ravulizumab-cwvz for Neuromyelitis Optica Spectrum Disorder
March 25th 2024The approval is supported by phase 3 data which showed ravulizumab-cwvz met its primary end point of time to first on-trial relapse, with no relapses observed in 58 patients with NMOSD over a median treatment duration of 73 weeks.
Targeting the NLRX1 Pathway for Neuroprotection in Multiple Sclerosis: Marjan Gharagozloo, PhD
March 25th 2024The assistant professor of neurology at Johns Hopkins Medicine talked about recent research that suggests activating the NLRX1 pathway could offer neuroprotection in multiple sclerosis. [WATCH TIME: 5 minutes]
Therapeutic Avenues for Multiple Sclerosis Through Immune Cell Communication: Jeffrey Huang, PhD
March 24th 2024The associate professor of biology at Georgetown University talked about how immune cells can communicate with brain cells to enhance repair processes, which may offer potential treatment targets for multiple sclerosis. [WATCH TIME: 5 minutes]
Lantheus Announces Collaboration With NIH to Study Tau Imaging Agent in Alzheimer Disease
March 23rd 2024The CLARiTI study spans across all 37 Alzheimer Disease Research Centers, collecting evidence on imaging and blood-based biomarkers to generate etiologic patient profiles of mixed dementia.
Overviewing Phase 2 SYNAPSE-SMA Trial of NMD670 for Spinal Muscular Atrophy: Jorge Quiroz, MD, MBA
March 22nd 2024The chief medical officer of NMD Pharma provided perspective on a newly launched phase 2 study assessing NMD670, a first-in-class neuromuscular transmission enhancer, in patients with spinal muscular atrophy type 3. [WATCH TIME: 5 minutes]
Clinical Significance of Visual System Modeling for Multiple Sclerosis Research: Shiv Saidha, MBBCh
March 21st 2024The professor of neurology at Johns Hopkins Medicine talked about modeling visual systems as an area of focus in clinical trials for multiple sclerosis as it may offer insights into neurodegeneration and neuroprotection. [WATCH TIME: 6 minutes]
Introducing Sleeping Around the Podcast × NeurologyLive
March 21st 2024Sleeping Around the Podcast is hosted by Anne Marie Morse, DO, FAASM, a neurologist with special qualifications in child neurology and a sleep medicine specialist, who has partnered with NeurologyLive to bring you bite-sized, sleep-focused content.
Interim Phase 2 Data Highlight IGC-AD1 as a Potential Therapy for Alzheimer Disease Agitation
March 20th 2024Over a 6-week period, patients taking IGC-AD1, on average, experienced a more significant reduction in agitation scores compared with those on placebo, with effects seen as early as week 2.